

# Clinical trials of EGFR inhibitors for lung cancer (metastatic) in 2nd line

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 TKI

Trial	Treatments	Patients	Trials design and methods
<b>gefitinib vs carboplatin-paclitaxel</b>			
Maemondo , 2010 [UMIN-CTR C000000376] n=NA	-	patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy	
<b>gefitinib vs docetaxel</b>			
ISTANA (Lee) , 2010 n=NA	-	previously treated advanced nonsmall-cell lung cancer	
V-15-32 (Maruyama) , 2008 n=NA	-	previously treated advanced nonsmall-cell lung cancer	
INTEREST (Kim) , 2008 n=NA	-	previously treated advanced nonsmall-cell lung cancer	
SIGN (Cufer) , 2006 n=NA	-	previously treated advanced nonsmall-cell lung cancer	
<b>gefitinib vs gefitinib</b>			
Kris , 2003 n=NA follow-up:	-	Patients either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens	double blind
<b>gefitinib vs placebo</b>			
EORTC 08021/ILCP 01/03 , 2011 [NCT00091156] n=NA	-	patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy	
ISEL , 2006 n=NA	-	patients of Asian origin with refractory advanced non-small cell lung cancer	
<b>osimertinib vs platinum-based therapy plus pemetrexed</b>			
AURA 3 , 2017 [NCT02151981] n=NA follow-up:	oral osimertinib (at a dose of 80 mg once daily) versus intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles	patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed after 1st-line EGFR tyrosine kinase inhibitor (TKI) therapy.	

## References

Maemondo, 2010:

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, , Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8. [20573926] [10.1056/NEJMoa0909530](https://doi.org/10.1056/NEJMoa0909530)

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, , Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8. [20573926] [10.1056/NEJMoa0909530](https://doi.org/10.1056/NEJMoa0909530)

#### **ISTANA (Lee), 2010:**

Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. *Clin Cancer Res* 2010;16:1307-14 [20145166] [10.1158/1078-0432.CCR-09-1903](https://doi.org/10.1158/1078-0432.CCR-09-1903)

#### **V-15-32 (Maruyama), 2008:**

Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. *J Clin Oncol* 2008;26:4244-52 [18779611] [10.1200/JCO.2007.15.0185](https://doi.org/10.1200/JCO.2007.15.0185)

Yamamoto N, Nishiwaki Y, Negoro S, Jiang H, Itoh Y, Saijo N, Fukuoka M, Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients. *J Thorac Oncol* 2010;5:1042-7. [20453692] [10.1097/JTO.0b013e3181da36db](https://doi.org/10.1097/JTO.0b013e3181da36db)

Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, Saijo N, Fukuoka M, Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. *Ann Oncol* 2009;20:1483-8. [19282468] [10.1093/annonc/mdp031](https://doi.org/10.1093/annonc/mdp031)

#### **INTEREST (Kim), 2008:**

Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. *Lancet* 2008;372:1809-18 [19027483] [10.1016/S0140-6736\(08\)61758-4](https://doi.org/10.1016/S0140-6736(08)61758-4)

#### **SIGN (Cufer), 2006:**

Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. *Anticancer Drugs* 2006;17:401-9 [16549997] [10.1097/01.cad.0000203381.99490.ab](https://doi.org/10.1097/01.cad.0000203381.99490.ab)

#### **Kris, 2003:**

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 2003;290:2149-58 [14570950]

#### **EORTC 08021/ILCP 01/03, 2011:**

Gaafar RM, Surrmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP, , A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). *Eur J Cancer* 2011;47:2331-40. [21802939] [10.1016/j.ejca.2011.06.045](https://doi.org/10.1016/j.ejca.2011.06.045)

#### **ISEL, 2006:**

Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, Yang CH, Tsao CJ, Watkins C, Botwood N, Thatcher N, Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. *J Thorac Oncol* 2006;1:847-55. [17409969]

Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* ;366:1527-37. [16257339] [10.1016/S0140-6736\(05\)67625-8](https://doi.org/10.1016/S0140-6736(05)67625-8)

#### **AURA 3, 2017:**

Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med* 2017 Feb 16;376:629-640 [27959700]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.